The latest price target for Genprex (NASDAQ:GNPX) was reported by HC Wainwright & Co. on May 17, 2024. The analyst firm set a price target for $10.00 expecting GNPX to rise to within 12 months (a possible 762.07% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Genprex (NASDAQ:GNPX) was provided by HC Wainwright & Co., and Genprex reiterated their buy rating.

There is no last upgrade for Genprex

There is no last downgrade for Genprex.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genprex, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genprex was filed on May 17, 2024 so you should expect the next rating to be made available sometime around May 17, 2025.

While ratings are subjective and will change, the latest Genprex (GNPX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Genprex (GNPX) is trading at is $1.16, which is out of the analyst’s predicted range.